Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas

Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.

Pill in crosshairs
Several congressional panels might hold drug pricing hearings in the coming weeks.

The 2019 congressional hearing season kicked off with dueling drug pricing hearings in the House and Senate that provided plenty of drama and tweetable moments – as well as repeated bipartisan promises that future hearings will shine a much harsher light on pharmaceutical company executives than what they have faced the past.

Unlike in recent years, mainstream pharmaceutical companies (and not just “bad actors” like Valeant and Turing) are now clearly in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet